Disorders Due to the Use of Synthetic Cannabinoids (ICD-11: 6C42)

1. Introduction

Disorders due to the use of synthetic cannabinoids represent a growing and relatively new challenge in global clinical practice. Unlike natural cannabis, synthetic cannabinoids are artificially produced chemical compounds that act as potent agonists of endogenous cannabinoid receptors, resulting in significantly more intense and unpredictable effects. Popularly known by various commercial names such as "Spice," "K2," or "herbal incense," these products are frequently marketed deceptively as "legal" or "safe" alternatives to traditional cannabis.

The clinical importance of this disorder cannot be underestimated. Synthetic cannabinoids present a substantially different risk profile from natural cannabis, with greater propensity to cause acute psychotic symptoms, significant physical dependence, and severe withdrawal syndrome. The variable chemical nature of these compounds—there are literally hundreds of different variants—makes diagnosis and treatment particularly challenging.

From a public health perspective, there is a concerning increase in acute intoxications requiring emergency care, including severe psychotic episodes, seizures, cardiovascular events, and even deaths. The most vulnerable population includes adolescents and young adults, frequently attracted by the erroneous perception of safety and the availability of these products.

Correct coding using the ICD-11 code 6C42 is critical for adequate epidemiological monitoring, health resource planning, clinical research, and implementation of effective public policies. The precise distinction between disorders related to natural cannabis and synthetic cannabinoids allows for more appropriate therapeutic interventions and deeper understanding of the patterns of use and consequences of these substances.

2. Correct ICD-11 Code

Code: 6C42

Description: Disorders due to use of synthetic cannabinoids

Parent category: Disorders due to substance use

Official definition: This code classifies disorders characterized by the pattern of use and adverse consequences resulting from the consumption of synthetic cannabinoids. These compounds are artificially synthesized chemical substances that function as potent agonists for endogenous cannabinoid receptors in the central nervous system. There are several hundred different chemical variants of these compounds.

The typical method of consumption involves spraying the synthetic compound onto plant material (such as dried cannabis leaves, tea, or other herbs) which is subsequently smoked. Crucially, the pharmacological effects of synthetic cannabinoids differ substantially from the effects of naturally cultivated cannabis. While natural cannabis may produce relatively controllable euphoria, synthetic cannabinoids frequently produce euphoric effects that are accompanied or even dominated by psychotic-like symptoms, including intense paranoia, visual and auditory hallucinations, and severely disorganized behavior.

Acute intoxication by synthetic cannabinoids presents more frequently with prominent psychotic manifestations, differing significantly from the pattern observed with natural cannabis. Additionally, these compounds produce physical and psychological dependence, with clinically recognized withdrawal syndromes. Mental disorders induced by synthetic cannabinoids, particularly induced psychotic disorder, are well-documented complications.

3. When to Use This Code

Code 6C42 should be used in specific clinical scenarios where there is clear evidence of synthetic cannabinoid use and related consequences:

Scenario 1: Acute psychotic episode following confirmed use A 22-year-old patient presents to the emergency department with intense psychomotor agitation, visual hallucinations of threatening creatures, severe paranoia, and disorganized behavior. Family members report that the patient smoked a product marketed as "herbal incense" approximately 30 minutes before symptom onset. There is no prior psychiatric history. Toxicological examination or reliable report confirms synthetic cannabinoid use. This is a typical case for 6C42 coding.

Scenario 2: Established dependence with withdrawal syndrome A patient with a history of daily synthetic cannabinoid use for a period exceeding six months presents with withdrawal symptoms when attempting to discontinue use: intense irritability, marked anxiety, severe insomnia, tremors, profuse sweating, and intense craving for the substance. The patient reports loss of control over use, unsuccessful attempts to cease consumption, and continued use despite evident negative consequences (job loss, family conflicts). Synthetic cannabinoid dependence is clearly established.

Scenario 3: Recurrent intoxication with functional impairment A patient presents with multiple episodes of synthetic cannabinoid intoxication characterized by severe tachycardia, hypertension, intense nausea, vomiting, mental confusion, and occasionally seizures. Recurrent use results in significant absenteeism, deterioration in academic or professional performance, and impairment of interpersonal relationships. The pattern of problematic use justifies 6C42 coding.

Scenario 4: Persistent induced psychotic disorder A patient develops psychotic symptoms (paranoid delusions, auditory hallucinations) that persist for weeks or months following synthetic cannabinoid use. Investigation excludes primary psychotic disorder, and there is clear temporal relationship between the onset of substance use and emergence of psychotic symptoms. This mental disorder induced by synthetic cannabinoids requires code 6C42.

Scenario 5: Problematic use with medical complications A patient with a history of regular synthetic cannabinoid use develops medical complications directly attributable to use: rhabdomyolysis, acute kidney injury, cardiovascular events (acute myocardial infarction in a young individual without other risk factors), or seizures. The pattern of use and serious medical consequences justify coding.

Scenario 6: Pattern of compulsive use with loss of control A patient reports use that initially was recreational but progressively became compulsive, with increased frequency and quantity consumed, development of tolerance (need for larger doses to obtain the same effect), substantial time spent obtaining and using the substance, and continued use despite recognition of physical and psychological harm.

4. When NOT to Use This Code

It is essential to distinguish situations where code 6C42 should not be applied:

Use of natural cannabis: If the patient is using exclusively naturally cultivated cannabis (traditional marijuana), even with a problematic pattern of use or dependence, the correct code is 6C41 - Disorders due to cannabis use, not 6C42. The distinction is critical because risk profiles, symptom patterns, and therapeutic approaches differ substantially.

Experimental use without consequences: A single episode of synthetic cannabinoid use without development of significant symptoms, without a pattern of repeated use, and without adverse consequences does not justify coding a disorder. Mere exposure does not constitute a disorder.

Primary psychotic symptoms: If the patient presents with a primary psychotic disorder (schizophrenia, schizoaffective disorder, delusional disorder) and occasionally uses synthetic cannabinoids, but the psychotic symptoms existed before and independently of substance use, the primary diagnosis is the psychotic disorder, not 6C42.

Intoxication from other substances: When the patient presents with symptoms related to the use of multiple substances simultaneously and it is not possible to determine that synthetic cannabinoids are the predominant cause, or when other substances (stimulants, hallucinogens, dissociatives) are clearly responsible for the clinical presentation, alternative codes should be considered.

Disorders due to alcohol or other substance use: If the problematic pattern of use primarily involves alcohol (code 6C40), opioids (code 6C43), stimulants, or other substances, the specific codes for those substances should be used. Multiple coding is appropriate when there are coexisting disorders due to multiple substance use.

Unrelated medical conditions: Symptoms that superficially may appear related to synthetic cannabinoid use, but that upon clinical investigation prove to be due to other medical conditions (epilepsy, encephalitis, metabolic disorders, intoxication from other substances) should not be coded as 6C42.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

Diagnostic confirmation requires systematic and comprehensive evaluation. Begin with detailed clinical history focusing specifically on the pattern of substance use: when it started, frequency, amount, route of administration, context of use, and progression over time.

Specifically investigate the use of synthetic cannabinoids, which can be identified by varied commercial names. Ask about products smoked and sold as "herbal incense," "herbal blends," or specific brands known locally. Many users do not recognize that they are using synthetic cannabinoids, believing they are using natural cannabis.

Assess the presence of dependence criteria: loss of control over use, compulsive use, development of tolerance, withdrawal symptoms when use is discontinued, substantial time spent in substance-related activities, continued use despite negative consequences, and impairment of important activities.

Examine characteristic intoxication symptoms: in addition to typical cannabis effects (red eyes, dry mouth, increased appetite), specifically look for psychotic symptoms (paranoia, hallucinations, thought disorganization), cardiovascular symptoms (tachycardia, hypertension), neurological symptoms (seizures, tremors), and gastrointestinal symptoms (nausea, severe vomiting).

Use standardized assessment instruments when available, such as screening questionnaires for problematic substance use adapted for synthetic cannabinoids. Toxicological tests can be useful, although many synthetic cannabinoids are not detected in standard urine tests, requiring specialized analyses.

Step 2: Verify Specifiers

Determine disorder severity based on the number of criteria present and the degree of functional impairment. Mild disorders involve few criteria and minimal impairment; moderate disorders present an intermediate number of criteria with notable functional impairment; severe disorders demonstrate many criteria with severe functional impairment.

Assess current status: acute intoxication, withdrawal, early remission (after cessation of use but with vulnerability to relapse), sustained remission (prolonged period without problematic use). Current status influences therapeutic planning.

Identify specific complications: presence of induced mental disorder (particularly psychotic disorder), medical complications (cardiovascular, renal, neurological), cognitive impairment, and impact on specific functional areas (occupational, academic, social, family).

Document the temporal pattern: episodic versus continuous use, frequency of intoxication episodes, duration of problematic use, previous attempts to cease or reduce use and their outcomes.

Step 3: Differentiate from Other Codes

6C40 - Disorders due to use of alcohol: The fundamental difference lies in the substance consumed. Alcohol produces intoxication characterized by disinhibition, motor incoordination, slurred speech, and impaired judgment, but rarely causes prominent psychotic symptoms at usual doses. Alcohol withdrawal can include tremors, sweating, anxiety, and in severe cases, delirium tremens with hallucinations, but the pattern differs from synthetic cannabinoid withdrawal. History of use, specific symptoms, and when available, laboratory confirmation allow clear distinction.

6C41 - Disorders due to use of cannabis: This is the most critical and potentially challenging distinction. Natural cannabis contains THC (tetrahydrocannabinol) as the main psychoactive component, usually in concentrations of 5-30%, along with CBD (cannabidiol) that modulates THC effects. Synthetic cannabinoids are complete agonists of cannabinoid receptors with much higher potency, without modulating CBD. Clinically, natural cannabis rarely causes intense psychotic symptoms in users without prior vulnerability, while synthetic cannabinoids frequently produce severe paranoia, hallucinations, and disorganization even on first use. The withdrawal syndrome is generally milder with natural cannabis. Careful history about the specific product used is essential.

6C43 - Disorders due to use of opioids: Opioids (heroin, morphine, oxycodone, fentanyl) produce euphoria, sedation, analgesia, and pupil constriction during intoxication. Opioid withdrawal is characterized by intense muscle pain, lacrimation, rhinorrhea, diarrhea, piloerection, and intense craving, but does not include the prominent psychotic symptoms seen with synthetic cannabinoids. Patterns of use, routes of administration, and medical consequences (risk of overdose with respiratory depression for opioids versus psychotic and cardiovascular symptoms for synthetic cannabinoids) are distinct.

Step 4: Necessary Documentation

Appropriate documentation should include:

Checklist of mandatory information:

Clear identification of the substance used (synthetic cannabinoid, with commercial or street names when known)
Detailed pattern of use: age of onset, duration of use, frequency, amount, route of administration
Diagnostic criteria present with specific examples of each criterion
Intoxication symptoms experienced, with emphasis on psychotic manifestations
Presence and characteristics of withdrawal syndrome if applicable
Medical, psychological, social, occupational, and legal consequences of use
Previous treatment attempts and their outcomes
Psychiatric and medical comorbidities
Family history of substance use disorders
Results of complementary tests (laboratory, toxicological, neuroimaging when performed)
Severity assessment and specifiers
Justification for the specific 6C42 code, differentiating from other substance use disorders

Clear and complete documentation is essential not only for continuity of care, but also for medico-legal purposes, research, and health policy planning.

6. Complete Practical Example

Clinical Case

Lucas, 19 years old, university student, is brought to the emergency department by friends after presenting bizarre and aggressive behavior on campus. On examination, he is extremely agitated, with disorganized speech, reporting that "demons are chasing" him and that "voices command" his actions. He presents with tachycardia (heart rate of 140 bpm), hypertension (blood pressure 160/100 mmHg), bilateral mydriasis, profuse diaphoresis, and tremors. He attempts to assault the staff, requiring restraint.

His friends report that Lucas smoked a product they purchased as "relaxing incense" approximately one hour before. They inform that Lucas has been using this product regularly over the past four months, initially on weekends, but recently almost daily. They noticed progressive changes: social isolation, frequent class absences, increasing irritability, and previous episodes of less intense "paranoia."

In subsequent investigation, after initial stabilization with benzodiazepines, Lucas reports that he started using the product out of curiosity and because it was "cool" and not detectable in drug tests. He progressively increased the frequency of use, developed a need to use larger quantities to obtain the same effect, and attempted to stop several times, but experienced intense anxiety, insomnia, irritability, and uncontrollable craving, leading to relapse.

Lucas admits that use has severely affected his academic performance (risk of failing multiple courses), caused serious family conflicts, and resulted in loss of important friendships. He recognizes that paranoia episodes are frightening and harmful, but feels unable to control his use. He denies use of other illicit substances, uses alcohol only occasionally and moderately. There is no significant prior personal or family psychiatric history.

Laboratory tests reveal mild rhabdomyolysis (elevated CPK) and preserved renal function. Standard urine toxicology test is negative for cannabis, but specialized analysis confirms the presence of synthetic cannabinoid metabolites.

Step-by-Step Coding

Criteria analysis:

Loss of control: Present - Lucas progressively increased the frequency of use beyond what was initially intended
Unsuccessful attempts to cease: Present - multiple attempts with relapses
Substantial time spent: Present - almost daily use with impact on time available for other activities
Intense craving: Present - reported during attempts to stop
Functional impairment: Present - severe academic impairment, family conflicts, loss of relationships
Continuation despite consequences: Present - continues using despite recognizing paranoia episodes and other harms
Tolerance: Present - need for larger quantities for the same effect
Withdrawal: Present - symptoms when attempting to stop (anxiety, insomnia, irritability, craving)

Code chosen: 6C42 - Disorders due to use of synthetic cannabinoids

Complete justification:

The code 6C42 is appropriate because: (1) there is confirmed use of synthetic cannabinoid, not natural cannabis; (2) multiple dependence criteria are present (at least six clearly identified criteria); (3) there is a pattern of problematic use with serious consequences in multiple life areas; (4) typical clinical presentation with prominent psychotic symptoms during intoxication; (5) recognizable withdrawal syndrome; (6) substantial severity justifying classification as a serious disorder.

Applicable complementary codes:

Additionally, one should consider coding the acute psychotic episode induced by synthetic cannabinoid as a substance-induced mental disorder, and documenting medical complications (rhabdomyolysis) with appropriate ICD-11 codes.

7. Related Codes and Differentiation

Within the Same Category

6C40: Disorders due to use of alcohol

When to use: For disorders related specifically to consumption of alcoholic beverages, including dependence, intoxication, withdrawal, and mental disorders induced by alcohol.

Main difference vs. 6C42: The substance is fundamentally different. Alcohol is a central nervous system depressant, while synthetic cannabinoids are cannabinoid receptor agonists. Intoxication patterns differ markedly: alcohol causes disinhibition, incoordination, and sedation, rarely with psychosis at usual doses; synthetic cannabinoids frequently cause prominent psychotic symptoms. Alcohol withdrawal can be medically dangerous with risk of seizures and delirium tremens, while withdrawal from synthetic cannabinoids, although uncomfortable, is rarely medically serious.

6C41: Disorders due to use of cannabis

When to use: For disorders related to use of naturally cultivated cannabis (traditional marijuana), including all forms of natural cannabis (smoked, vaporized, edibles).

Main difference vs. 6C42: This is the most critical distinction. Natural cannabis contains THC in relatively moderate concentrations with CBD that modulates the effects. Synthetic cannabinoids are much more potent complete agonists without CBD. Clinically, natural cannabis rarely causes intense acute psychotic symptoms, except in vulnerable individuals or with very high doses, while synthetic cannabinoids frequently produce severe paranoia, hallucinations, and agitation even in users without prior vulnerability. Withdrawal syndrome tends to be more intense with synthetic cannabinoids. Serious medical complications (cardiovascular events, seizures, rhabdomyolysis) are much more common with synthetic cannabinoids.

6C43: Disorders due to use of opioids

When to use: For disorders related to use of natural, semisynthetic, or synthetic opioids (heroin, morphine, codeine, oxycodone, fentanyl, tramadol).

Main difference vs. 6C42: Opioids produce euphoria, sedation, analgesia, and pupillary constriction. Opioid intoxication is characterized by sedation and risk of potentially fatal respiratory depression, not by psychotic symptoms. Opioid withdrawal is intensely uncomfortable with muscle aches, gastrointestinal and autonomic symptoms, but does not include the psychotic symptoms seen with synthetic cannabinoids. The risk of fatal overdose is much higher with opioids due to respiratory depression.

Differential Diagnoses

Primary psychotic disorder (schizophrenia, schizoaffective disorder): Distinguished by the presence of psychotic symptoms before and independent of substance use, chronic course, frequent family history of psychosis, and absence of clear temporal relationship between substance use and emergence of symptoms.

Intoxication by other substances: Stimulants (amphetamines, cocaine) can cause paranoia and agitation, but generally with greater component of euphoria and energy; hallucinogens (LSD, psilocybin) cause perceptual distortions and elaborate visual hallucinations, but generally with preserved insight; dissociatives (PCP, ketamine) cause disconnection from reality but with distinct phenomenological pattern.

Medical conditions: Encephalitis, meningitis, metabolic states (hypoglycemia, hypernatremia), epilepsy, and other neurological conditions can present with altered mental status and psychotic symptoms, but appropriate clinical and laboratory investigation allows differentiation.

8. Differences with ICD-10

In ICD-10, there was no specific code for disorders due to the use of synthetic cannabinoids. These cases were typically coded under F12 (Mental and behavioral disorders due to use of cannabinoids), the same code used for natural cannabis, or occasionally under F19 (Mental and behavioral disorders due to use of multiple drugs and use of other psychoactive substances).

The main change in ICD-11 is the specific recognition of synthetic cannabinoids as a distinct category (6C42), separate from natural cannabis (6C41). This differentiation reflects the growing scientific and clinical recognition that synthetic cannabinoids represent a class of substances with a risk profile, symptom pattern, and consequences substantially different from natural cannabis.

The practical impact of these changes is significant. Separate coding allows: (1) more precise epidemiological monitoring of the prevalence and incidence of problems related to synthetic cannabinoids; (2) identification of populations at specific risk; (3) appropriate allocation of health resources for treatment; (4) development of specific therapeutic protocols; (5) focused research on the unique characteristics of these disorders; (6) public policies based on more precise data.

For health professionals, the transition from ICD-10 to ICD-11 requires careful attention to distinguish natural cannabis from synthetic cannabinoids during clinical assessment, ensuring appropriate coding that accurately reflects the substance involved.

9. Frequently Asked Questions

1. How is the diagnosis of disorders due to the use of synthetic cannabinoids made?

The diagnosis is primarily clinical, based on a detailed history of the pattern of use and evaluation of diagnostic criteria. It is essential to specifically ask about the type of product used, as many users do not recognize that they are using synthetic cannabinoids. Toxicological tests can assist, but many synthetic cannabinoids are not detected in standard urine tests, requiring specialized analyses that are not always available. The characteristic clinical presentation - particularly prominent psychotic symptoms during intoxication - provides an important clue. Assessment of consequences of use in multiple areas of life (health, relationships, work, legal) is fundamental.

2. Is treatment available in public health systems?

The availability of specialized treatment varies considerably among different health systems and regions. Many public health systems offer services for substance use disorders that can serve patients with problems related to synthetic cannabinoids, although specific protocols are still under development. Treatment generally includes detoxification when necessary, psychosocial interventions (cognitive-behavioral therapy, motivational interviewing, relapse prevention), management of psychiatric comorbidities, and social support. Access to specialized services may be limited in some regions, but general mental health and substance abuse services can provide adequate care.

3. How long does treatment last?

The duration of treatment varies substantially depending on the severity of the disorder, presence of complications, comorbidities, and individual response. The acute phase of detoxification and stabilization generally lasts days to weeks. Intensive outpatient treatment may extend for several months. Maintenance programs and relapse prevention often continue for a year or more. Severe disorders with multiple relapses may require repeated episodes of treatment or long-term follow-up. It is important to recognize that substance use disorders are often chronic recurrent conditions, and multiple episodes of treatment do not represent failure, but part of the recovery process.

4. Can this code be used in medical certificates?

Yes, code 6C42 can be used in medical documentation, including certificates when clinically appropriate and necessary. However, considerations of confidentiality and stigma should be weighed. In many situations, it may be appropriate to use more general terms in documents that will be seen by employers or other parties, reserving specific coding for confidential medical documentation. The decision should balance the need for accurate documentation with protection of patient privacy and minimization of potential discrimination. Open discussion with the patient about documentation is recommended.

5. Are synthetic cannabinoids more dangerous than natural cannabis?

Clinical and scientific evidence indicates yes, synthetic cannabinoids present a significantly higher risk profile than natural cannabis. They are more potent, produce psychotic symptoms with greater frequency and intensity, more frequently cause serious medical complications (cardiovascular events, seizures, rhabdomyolysis, renal insufficiency), and have greater potential for dependence. The absence of CBD (present in natural cannabis) that modulates the effects of THC, combined with much greater potency as cannabinoid receptor agonists, partially explains the greater risk. The variable and unpredictable chemical composition of products marketed as synthetic cannabinoids adds substantial risk.

6. Is there specific medication to treat synthetic cannabinoid dependence?

Currently, there are no medications specifically approved for treatment of synthetic cannabinoid dependence. Treatment is primarily based on psychosocial interventions. Medications can be used for symptomatic management: benzodiazepines for acute agitation and anxiety during withdrawal; antipsychotics for psychotic symptoms when necessary; medications for insomnia, nausea, or other specific symptoms. Research is ongoing investigating potential pharmacotherapies, but to date, structured psychosocial approaches represent the cornerstone of treatment.

7. Who is at greater risk of developing problems with synthetic cannabinoids?

Adolescents and young adults represent a particularly vulnerable population, often attracted by the mistaken perception that synthetic cannabinoids are "legal" or "safe." Individuals with a history of other substance use disorders, psychiatric disorders (particularly mood and anxiety disorders), history of trauma, dysfunctional family environment, and lack of social support are at increased risk. Easy availability and deceptive marketing of products as "natural" or "incense" contribute to experimental use that may progress to problematic use.

8. Are psychotic symptoms caused by synthetic cannabinoids permanent?

In most cases, psychotic symptoms induced by synthetic cannabinoids resolve after the substance is eliminated from the body, generally within days to weeks. However, some individuals develop persistent psychotic symptoms that continue for months or, rarely, permanently. Risk factors for persistent psychosis include: genetic vulnerability to psychotic disorders, repeated or prolonged use, high doses, young age at onset of use, and presence of prodromal psychotic symptoms before use. Early intervention and appropriate treatment improve prognosis. Some cases may represent primary psychotic disorder precipitated or unmasked by the use of synthetic cannabinoids.

Conclusion: ICD-11 code 6C42 represents an important advance in the recognition of disorders due to the use of synthetic cannabinoids as a distinct clinical entity with specific characteristics, risks, and therapeutic needs. Precise coding is essential for epidemiological monitoring, resource planning, development of effective treatments, and protection of public health. Health professionals should be alert to the critical differences between synthetic cannabinoids and natural cannabis, ensuring careful evaluation and appropriate coding that accurately reflects the substance involved and the severity of the disorder.

External References

This article was developed based on reliable scientific sources:

References verified on 2026-02-03

Disorders due to the use of synthetic cannabinoids

Compartilhar